Oklahoma State University Center for Health Sciences, Tulsa, OK, United States.
Oklahoma State University Center for Health Sciences, Tulsa, OK, United States.
Eur J Obstet Gynecol Reprod Biol. 2022 Feb;269:24-29. doi: 10.1016/j.ejogrb.2021.12.021. Epub 2021 Dec 20.
Reproducibility is a core tenet of scientific research. A reproducible study is one where the results can be recreated by using the same methodology and materials as the original researchers. Unfortunately, reproducibility is not a standard to which the majority of research is currently adherent.
Our cross-sectional survey evaluated 300 trials in the field of Obstetrics and Gynecology. Our primary objective was to identify nine indicators of reproducibility and transparency. These indicators include availability of data, analysis scripts, pre-registration information, study protocols, funding source, conflict of interest statements and whether or not the study was available via Open Access.
Of the 300 trials in our sample, 208 contained empirical data that could be assessed for reproducibility. None of the trials in our sample provided a link to their protocols or provided a statement on availability of materials. None were replication studies. Just 10.58% provided a statement regarding their data availability, while only 5.82% provided a statement on preregistration. 25.85% failed to report the presence or absence of conflicts of interest and 54.08% did not state the origin of their funding.
In the studies we examined, research in the field of Obstetrics and Gynecology is not consistently reproducible and frequently lacks conflict of interest disclosure. Consequences of this could be far-reaching and include increased research waste, widespread acceptance of misleading results and erroneous conclusions guiding clinical decision-making.
可重复性是科学研究的核心原则之一。可重复性研究是指使用与原始研究人员相同的方法和材料可以重现结果的研究。不幸的是,目前大多数研究都不符合可重复性标准。
我们的横断面调查评估了妇产科领域的 300 项试验。我们的主要目标是确定九个可重复性和透明度指标。这些指标包括数据、分析脚本、预注册信息、研究方案、资金来源、利益冲突声明以及研究是否通过开放获取提供。
在我们的样本中,300 项试验中有 208 项包含可用于评估可重复性的经验数据。我们样本中的试验都没有提供其方案的链接,也没有提供关于材料可用性的声明。没有一项是复制研究。只有 10.58%的试验提供了关于其数据可用性的声明,而只有 5.82%的试验提供了关于预注册的声明。25.85%的试验没有报告利益冲突的存在或不存在,54.08%的试验没有说明其资金来源。
在我们检查的研究中,妇产科领域的研究不一致,且经常缺乏利益冲突披露。其后果可能是深远的,包括增加研究浪费、广泛接受误导性结果以及错误结论指导临床决策。